Figure 3.

Incidence of Grade ≥2 acute rectal toxicity as a function of fractional mean dose in subgroups of patients treated with (6 groups, 24–25 patients each) or without (7 groups, 51–52 patients each) neoadjuvant hormone therapy. Points and error bars are as in Figure 2. Solid curves show the fit of the Lyman-Kutcher-Burman model with hormone therapy included as a dose-modifying factor on the fractional TD₅₀ value.